PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29573334-0	2018	FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.	regorafenib	52-63	fibroblast growth factor receptor 2	Homo sapiens	0-5	
29573334-3	2018	Mutation profiles and copy number assays of regorafenib target molecules indicated that amplification of fibroblast growth factor receptor 2 (FGFR2) was the only genetic alteration associated with in vitro sensitivity to regorafenib.	regorafenib	221-232	fibroblast growth factor receptor 2	Homo sapiens	105-140	
29573334-3	2018	Mutation profiles and copy number assays of regorafenib target molecules indicated that amplification of fibroblast growth factor receptor 2 (FGFR2) was the only genetic alteration associated with in vitro sensitivity to regorafenib.	regorafenib	221-232	fibroblast growth factor receptor 2	Homo sapiens	142-147	
29573334-4	2018	Regorafenib effectively inhibited phosphorylation of FGFR2 and its downstream signaling molecules in a dose-dependent manner and selectively in FGFR2-amplified cells.	regorafenib	0-11	fibroblast growth factor receptor 2	Homo sapiens	53-58	
29573334-4	2018	Regorafenib effectively inhibited phosphorylation of FGFR2 and its downstream signaling molecules in a dose-dependent manner and selectively in FGFR2-amplified cells.	regorafenib	0-11	fibroblast growth factor receptor 2	Homo sapiens	144-149	
29573334-7	2018	Regorafenib effectively abrogates activated FGFR2 signaling in FGFR2-amplified gastric and colorectal cancer and, therefore, might be considered for integration into treatment in patients with FGFR2-amplified gastric and colorectal cancers.	regorafenib	0-11	fibroblast growth factor receptor 2	Homo sapiens	44-49	
29573334-7	2018	Regorafenib effectively abrogates activated FGFR2 signaling in FGFR2-amplified gastric and colorectal cancer and, therefore, might be considered for integration into treatment in patients with FGFR2-amplified gastric and colorectal cancers.	regorafenib	0-11	fibroblast growth factor receptor 2	Homo sapiens	63-68	
29573334-7	2018	Regorafenib effectively abrogates activated FGFR2 signaling in FGFR2-amplified gastric and colorectal cancer and, therefore, might be considered for integration into treatment in patients with FGFR2-amplified gastric and colorectal cancers.	regorafenib	0-11	fibroblast growth factor receptor 2	Homo sapiens	63-68